Drug-induced phototoxicity evoked by inhibition of human ABC transporter ABCG2: development of in vitro high-speed screening systems

Bibliography

• Stein KR, Scheinfeld NS. Drug-induced photoallergic and phototoxic reactions. Expert Opin Drug Saf 2007;6(4):431-43
   PubMed Web of Science ®Google Scholar
• Dubakiene R, Kupriene M. Scientific problems of photosensitivity. Medicina (Kaunas) 2006;42(8):619-24
   PubMedGoogle Scholar
• Ferguson J. Photosensitivity due to drugs. Photodermatol Photoimmunol Photomed 2002;18(5):262-9
   PubMed Web of Science ®Google Scholar
• Moore D. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf 2002;25(5):345-72
   PubMed Web of Science ®Google Scholar
• Vassileva SG, Mateev G, Parish LC. Antimicrobial photosensitive reactions. Arch Intern Med 1998;158(18):1993-2000
   PubMed Web of Science ®Google Scholar
• Allen JE. Drug-induced photosensitivity. Clin Pharm 1993;12(8):580-7
   PubMedGoogle Scholar
• IARC monographs on the evaluation of carcinogenic risks to humans. Solar and ultraviolet radiation. IARC Monogr Eval Carcinog Risks Hum 1992;55:1-316
   PubMedGoogle Scholar
• Marks R. Epidemiology of non-melanoma skin cancer and solar keratoses in Australia: a tale of self-immolation in Elysian fields. Aust J Dermatol 1997;38(Suppl 1):S26-9
   PubMed Web of Science ®Google Scholar
• Rusonis ES, Rusonis PA, Miller C, Oken HA. Skin cancer detection and prevention: a community program promoting sun safe behaviors. Md Med J 1999;48(4):169-72
   PubMedGoogle Scholar
• NPC Center for Phototoxicology at FDA/NCTR. Available from: URL: www.fda.gov/nctr/science/centers/phototoxicology/index.htm [Last accessed 5 February 2008]
   Google Scholar
• Svensson CK, Cowen EW, Gaspari AA. Cutaneous drug reactions. Pharmacol Rev 2001;53(3):357-79
   PubMed Web of Science ®Google Scholar
• Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356(9237):1255-9
   PubMed Web of Science ®Google Scholar
• Ramsay CA, Obreshkova E. Photosensitivity from nalidixic acid. Br J Dermatol 1974;91(5):523-8
   PubMed Web of Science ®Google Scholar
• Baes H. Photosensitivity caused by nalidixic acid. Dermatologica 1968;136:61-4
   Google Scholar
• Przybilla B, Georgii A, Bergner T, Ring J. Demonstration of quinolone phototoxicity in vitro. Dermatologica 1990;181(2):98-103
   PubMedGoogle Scholar
• Sanders WE, Sanders CC. Fluoroquinolones in the Treatment of Infectious Diseases Glenview, IL: Physicians and Scientists Publishing Co.; 1990
   Google Scholar
• Wolfson JS, Hooper DC. Quinolone antimicrobial agents. Washington, DC: American Society for Microbiology; 1989
   Google Scholar
• Percival A. The appropriate use of quinolones. Drugs 1996;52(Suppl 2):34-6
   PubMed Web of Science ®Google Scholar
• Moellering RC Jr. The place of quinolones in everyday clinical practice. Chemotherapy 1996;42(Suppl 1):54-61
   PubMed Web of Science ®Google Scholar
• Stahlmann R. Safety profile of the quinolones. J Antimicrob Chemother 1990;26(Suppl D):31-44
   PubMedGoogle Scholar
• Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 1989;2(4):378-424
   PubMed Web of Science ®Google Scholar
• Mirensky YM, Parish LC. Photosensitivity and the quinolones. J Eur Acad Dermatol Venereol 1995;4:1-4
   Google Scholar
• Tokura Y, Iwamoto Y, Mizutani K, Takigawa M. Sparfloxacin phototoxicity: potential photoaugmentation by ultraviolet A and B sources. Arch Dermatol Res 1996;288(1):45-50
   PubMed Web of Science ®Google Scholar
• Gonzalez E, Gonzalez S. Drug photosensitivity, idiopathic photodermatoses, and sunscreens. J Am Acad Dermatol 1996;35(6):871-85; quiz 86-7
   PubMed Web of Science ®Google Scholar
• Iwamoto Y, Kurita A, Shimizu T, et al. DNA strand-breaking activities of quinolone antimicrobial agents under visible light irradiation. Biol Pharm Bull 1994;17(5):654-7
   PubMed Web of Science ®Google Scholar
• Alarcon-Segovia D, Kraus A. Drug-related lupus syndromes and their relationship to spontaneously occurring systemic lupus erythematosus. Baillieres Clin Rheumatol 1991;5(1):1-12
   PubMedGoogle Scholar
• Norrby SR, Lietman PS. Safety and tolerability of fluoroquinolones. Drugs 1993;45(Suppl 3):59-64
   PubMedGoogle Scholar
• Neyfakh AA, Borsch CM, Kaatz GW. Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter. Antimicrob Agents Chemother 1993;37(1):128-9
   PubMed Web of Science ®Google Scholar
• Munoz-Bellido JL, Alonzo Manzanares M, Martinez Andres JA, et al. Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA. Antimicrob Agents Chemother 1999;43(2):354-6
   PubMed Web of Science ®Google Scholar
• Jellen-Ritter AS, Kern WV. Enhanced expression of the multidrug efflux pumps AcrAB and AcrEF associated with insertion element transposition in Escherichia coli mutants Selected with a fluoroquinolone. Antimicrob Agents Chemother 2001;45(5):1467-72
   PubMed Web of Science ®Google Scholar
• Quinn T, O'Mahony R, Baird AW, et al. Multi-drug resistance in Salmonella enterica: efflux mechanisms and their relationships with the development of chromosomal resistance gene clusters. Curr Drug Targets 2006;7(7):849-60
   PubMed Web of Science ®Google Scholar
• Alvarez AI, Perez M, Prieto JG, et al. Fluoroquinolone efflux mediated by ABC transporters. J Pharm Sci 2008;In press
   Google Scholar
• Lowes S, Simmons NL. Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells. Br J Pharmacol 2002;135(5):1263-75
   PubMed Web of Science ®Google Scholar
• Merino G, Alvarez AI, Pulido MM, et al. Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos 2006;34(4):690-5
   PubMed Web of Science ®Google Scholar
• De Maat MM, Ekhart GC, Huitema AD, et al. Drug interactions between antiretroviral drugs and comedicated agents. Clin Pharmacokinet 2003;42(3):223-82
   PubMed Web of Science ®Google Scholar
• Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001;344(13):984-96
   PubMed Web of Science ®Google Scholar
• Dasgupta A, Okhuysen PC. Pharmacokinetic and other drug interactions in patients with AIDS. Ther Drug Monit 2001;23(6):591-605
   PubMed Web of Science ®Google Scholar
• Pappert A, Grossman M, Deleo V. Photosensitivity as the presenting illness in four patients with human immunodeficiency viral infection. Arch Dermatol 1994;130(5):618-23
   PubMed Web of Science ®Google Scholar
• Meola T, Sanchez M, Lim HW, et al. Chronic actinic dermatitis associated with human immunodeficiency virus infection. Br J Dermatol 1997;137(3):431-6
   PubMed Web of Science ®Google Scholar
• Vin-Christian K, Epstein JH, Maurer TA, et al. Photosensitivity in HIV-infected individuals. J Dermatol 2000;27(6):361-9
   PubMedGoogle Scholar
• Newell A, Avila C, Rodgers ME. Photosensitivity reaction of efavirenz. Sex Transm Infect 2000;76(3):221
   PubMed Web of Science ®Google Scholar
• Treudler R, Husak R, Raisova M, et al. Efavirenz-induced photoallergic dermatitis in HIV. Aids 2001;15(8):1085-6
   PubMed Web of Science ®Google Scholar
• Furue M. Photosensitive drug eruption induced by efavirenz in a patient with HIV infection. Intern Med 2004;43(7):533
   PubMed Web of Science ®Google Scholar
• Yoshimoto E, Konishi M, Takahashi K, et al. The first case of efavirenz-induced photosensitivity in a Japanese patient with HIV infection. Intern Med 2004;43(7):630-1
   PubMed Web of Science ®Google Scholar
• Savage DG, Antman KH. Imatinib mesylate-a new oral targeted therapy. N Engl J Med 2002;346(9):683-93
   PubMed Web of Science ®Google Scholar
• Peggs K, Mackinnon S. Imatinib mesylate-the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 2003;348(11):1048-50
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346(9):645-52
   PubMed Web of Science ®Google Scholar
• Brouard M, Saurat JH. Cutaneous reactions to STI571. N Engl J Med 2001;345(8):618-9
   PubMed Web of Science ®Google Scholar
• Rousselot P, Larghero J, Raffoux E, et al. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate. Br J Haematol 2003;120(6):1091-2
   PubMed Web of Science ®Google Scholar
• Valeyrie L, Bastuji-Garin S, Revuz J, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003;48(2):201-6
   PubMed Web of Science ®Google Scholar
• Raanani P, Goldman JM, Ben-Bassat I. Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571. J Clin Oncol 2002;20(3):869-70
   PubMed Web of Science ®Google Scholar
• Brazzelli V, Prestinari F, Barbagallo T, et al. A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients. J Eur Acad Dermatol Venereol 2007;21(3):384-7
   PubMed Web of Science ®Google Scholar
• Epstein JH, Seibert JS. Porphyria-like cutaneous changes induced by tetracycline hydrochloride photosensitization. Arch Dermatol 1976;112(5):661-6
   PubMed Web of Science ®Google Scholar
• Judd LE, Henderson DW, Hill DC. Naproxen-induced pseudoporphyria. A clinical and ultrastructural study. Arch Dermatol 1986;122(4):451-4
   PubMed Web of Science ®Google Scholar
• Bilsland D, Douglas WS. Sunbed pseudoporphyria induced by nalidixic acid. Br J Dermatol 1990;123(4):547
   PubMed Web of Science ®Google Scholar
• Sharp MT, Horn TD. Pseudoporphyria induced by voriconazole. J Am Acad Dermatol 2005;53(2):341-5
   PubMed Web of Science ®Google Scholar
• Hawk JL. Skin changes resembling hepatic cutaneous porphyria induced by oxytetracycline photosensitization. Clin Exp Dermatol 1980;5(3):321-5
   PubMed Web of Science ®Google Scholar
• Burry JN, Lawrence JR. Phototoxic blisters from high frusemide dosage. Br J Dermatol 1976;94(5):495-9
   PubMed Web of Science ®Google Scholar
• Petersen CS, Thomsen K. Pseudoporphyria. Ugeskr Laeger 1992;154(24):1713-5
   PubMedGoogle Scholar
• Laduca JR, Bouman PH, Gaspari AA. Nonsteroidal antiinflammatory drug-induced pseudoporphyria: a case series. J Cutan Med Surg 2002;6(4):320-6
   PubMed Web of Science ®Google Scholar
• Al-Khenaizan S, Schechter JF, Sasseville D. Pseudoporphyria induced by propionic acid derivatives. J Cutan Med Surg 1999;3(3):162-6
   PubMed Web of Science ®Google Scholar
• Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer 2003;3(5):380-7
   PubMed Web of Science ®Google Scholar
• Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst 1998;90(12):889-905
   PubMed Web of Science ®Google Scholar
• Usuda J, Kato H, Okunaka T, et al. Photodynamic therapy (PDT) for lung cancers. J Thorac Oncol 2006;1(5):489-93
   PubMed Web of Science ®Google Scholar
• Fien SM, Oseroff AR. Photodynamic therapy for non-melanoma skin cancer. J Natl Compr Canc Netw 2007;5(5):531-40
   PubMedGoogle Scholar
• Ackroyd R, Kelty C, Brown N, Reed M. The history of photodetection and photodynamic therapy. Photochem Photobiol 2001;74(5):656-69
   PubMed Web of Science ®Google Scholar
• Zeitouni NC, Oseroff AR, Shieh S. Photodynamic therapy for nonmelanoma skin cancers. Current review and update. Mol Immunol 2003;39(17-18):1133-6
   PubMed Web of Science ®Google Scholar
• Piaserico S, Belloni Fortina A, Rigotti P, et al. Topical photodynamic therapy of actinic keratosis in renal transplant recipients. Transplant Proc 2007;39(6):1847-50
   PubMed Web of Science ®Google Scholar
• Clark C, Bryden A, Dawe R, et al. Topical 5-aminolaevulinic acid photodynamic therapy for cutaneous lesions: outcome and comparison of light sources. Photodermatol Photoimmunol Photomed 2003;19(3):134-41
   PubMed Web of Science ®Google Scholar
• Rhodes LE, De Rie MA, Leifsdottir R, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol 2007;143(9):1131-6
   PubMed Web of Science ®Google Scholar
• Liu W, Baer MR, Bowman MJ, et al. The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res 2007;13(8):2463-70
   PubMed Web of Science ®Google Scholar
• Krishnamurthy PC, Du G, Fukuda Y, et al. Identification of a mammalian mitochondrial porphyrin transporter. Nature 2006;443(7111):586-9
   PubMed Web of Science ®Google Scholar
• Jonker JW, Buitelaar M, Wagenaar E, et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 2002;99(24):15649-54
   PubMed Web of Science ®Google Scholar
• Norman RA. Past and future: porphyria and porphyrins. Skinmed 2005;4(5):287-92
   PubMedGoogle Scholar
• Sarkadi B, Homolya L, Szakacs G, Varadi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 2006;86(4):1179-236
   PubMed Web of Science ®Google Scholar
• Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998;95(26):15665-70
   PubMed Web of Science ®Google Scholar
• Allikmets R, Schriml LM, Hutchinson A, et al. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 1998;58(23):5337-9
   PubMed Web of Science ®Google Scholar
• Miyake K, Mickley L, Litman T, et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 1999;59(1):8-13
   PubMed Web of Science ®Google Scholar
• Bailey-Dell KJ, Hassel B, Doyle LA, Ross DD. Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochim Biophys Acta 2001;1520(3):234-41
   PubMed Web of Science ®Google Scholar
• Kage K, Fujita T, Sugimoto Y. Role of Cys-603 in dimer/oligomer formation of the breast cancer resistance protein BCRP/ABCG2. Cancer Sci 2005;96(12):866-72
   PubMed Web of Science ®Google Scholar
• Henriksen U, Fog JU, Litman T, Gether U. Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2. J Biol Chem 2005;280(44):36926-34
   PubMed Web of Science ®Google Scholar
• Wakabayashi K, Nakagawa H, Adachi T, et al. Identification of cysteine residues critically involved in homodimer formation and protein expression of human ATP-binding cassette transporter ABCG2: a new approach using the flp recombinase system. J Exp Ther Oncol 2006;5(3):205-22
   PubMedGoogle Scholar
• Zhou S, Zong Y, Ney PA, et al. Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels. Blood 2005;105(6):2571-6
   PubMed Web of Science ®Google Scholar
• Krishnamurthy P, Ross DD, Nakanishi T, et al. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 2004;279(23):24218-25
   PubMed Web of Science ®Google Scholar
• Latunde-Dada GO, Simpson RJ, Mckie AT. Recent advances in mammalian haem transport. Trends Biochem Sci 2006;31(3):182-8
   PubMed Web of Science ®Google Scholar
• Krishnamurthy P, Schuetz JD. Role of ABCG2/BCRP in biology and medicine. Ann Rev Pharmacol Toxicol 2006;46:381-410
   PubMed Web of Science ®Google Scholar
• Tamura A, Onishi Y, An R, et al. In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs. Drug Metab Pharmacokinet 2007;22(6):428-40
   PubMed Web of Science ®Google Scholar
• Tamura A, Watanabe M, Saito H, et al. Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport. Mol Pharmacol 2006;70(1):287-96
   PubMed Web of Science ®Google Scholar
• Robey RW, Steadman K, Polgar O, Bates SE. ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy. Cancer Biol Ther 2005;4(2):187-94
   PubMed Web of Science ®Google Scholar
• Fraunfelder FW, Solomon J, Druker BJ, et al. Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther 2003;19(4):371-5
   PubMed Web of Science ®Google Scholar
• Zhang S, Yang X, Morris ME. Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. Pharm Res 2004;21(7):1263-73
   PubMed Web of Science ®Google Scholar
• Henrich CJ, Bokesch HR, Dean M, et al. A high-throughput cell-based assay for inhibitors of ABCG2 activity. J Biomol Screen 2006;11(2):176-83
   PubMed Web of Science ®Google Scholar
• Henrich CJ, Robey RW, Bokesch HR, et al. New inhibitors of ABCG2 identified by high-throughput screening. Mol Cancer Ther 2007;6(12):3271-8
   PubMed Web of Science ®Google Scholar
• Cooray HC, Janvilisri T, Van Veen HW, et al. Interaction of the breast cancer resistance protein with plant polyphenols. Biochem Biophys Res Commun 2004;317(1):269-75
   PubMed Web of Science ®Google Scholar
• Ahmed-Belkacem A, Pozza A, Munoz-Martinez F, et al. Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. Cancer Res 2005;65(11):4852-60
   PubMed Web of Science ®Google Scholar
• Katayama K, Masuyama K, Yoshioka S, et al. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship. Cancer Chemother Pharmacol 2007;60(6):789-97
   PubMed Web of Science ®Google Scholar
• Bernd A, Simon S, Ramirez Bosca A, et al. Phototoxic effects of Hypericum extract in cultures of human keratinocytes compared with those of psoralen. Photochem Photobiol 1999;69(2):218-21
   PubMed Web of Science ®Google Scholar
• Traynor NJ, Beattie PE, Ibbotson SH, et al. Photogenotoxicity of hypericin in HaCaT keratinocytes: implications for St. John's Wort supplements and high dose UVA-1 therapy. Toxicol Lett 2005;158(3):220-4
   PubMed Web of Science ®Google Scholar
• Wielgus AR, Chignell CF, Miller DS, et al. Phototoxicity in human retinal pigment epithelial cells promoted by hypericin, a component of St. John's wort. Photochem Photobiol 2007;83(3):706-13
   PubMed Web of Science ®Google Scholar
• Pirmohamed M. Pharmacogenetics and pharmacogenomics. Br J Clin Pharmacol 2001;52(4):345-7
   PubMed Web of Science ®Google Scholar
• Taylor JG, Choi EH, Foster CB, Chanock SJ. Using genetic variation to study human disease. Trends Mol Med 2001;7(11):507-12
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Tsuji A, Inui K, et al. The genetic polymorphism of drug transporters: functional analysis approaches. Pharmacogenomics 2004;5(1):67-99
   PubMed Web of Science ®Google Scholar
• Wakabayashi K, Tamura A, Saito H, et al. Human ABC transporter ABCG2 in xenobiotic protection and redox biology. Drug Metab Rev 2006;38(3):371-91
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Tamura A, Saito H, et al. Pharmacogenomics of the human ABC transporter ABCG2: from functional evaluation to drug molecular design. Naturwissenschaften 2005;92(10):451-63
   PubMed Web of Science ®Google Scholar
• Tamura A, Wakabayashi K, Onishi Y, et al. Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2. Cancer Sci 2007;98(2):231-9
   PubMed Web of Science ®Google Scholar
• Jitsukawa K, Suizu R, Hidano A. Chlorella photosensitization. New phytophotodermatosis. Int J Dermatol 1984;23(4):263-8
   PubMed Web of Science ®Google Scholar
• Bowers AG. Phytophotodermatitis. Am J Contact Dermat 1999;10(2):89-93
   PubMedGoogle Scholar
• Millard TP, Hawk JL. Photosensitivity disorders: cause, effect and management. Am J Clin Dermatol 2002;3(4):239-46
   PubMedGoogle Scholar
• Millard TP, Kirk A, Ratnavel R. Cutaneous hyperpigmentation during therapy with hydroxychloroquine. Clin Exp Dermatol 2004;29(1):92-3
   PubMed Web of Science ®Google Scholar
• Weiss J, Rose J, Storch CH, et al. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 2007;59(2):238-45
   PubMed Web of Science ®Google Scholar
• Robey RW, Shukla S, Steadman K, et al. Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure. Mol Cancer Ther 2007;6(6):1877-85
   PubMed Web of Science ®Google Scholar
• Cusatis G, Gregorc V, Li J, et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 2006;98(23):1739-42
   PubMed Web of Science ®Google Scholar
• Yanase K, Tsukahara S, Asada S, et al. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther 2004;3(9):1119-25
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Germain GS, Harwood FC, et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 2004;64(7):2333-7
   PubMed Web of Science ®Google Scholar
• Saito H, Hirano H, Nakagawa H, et al. A new strategy of high-speed screening and quantitative structure-activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions. J Pharmacol Exp Ther 2006;317(3):1114-24
   PubMed Web of Science ®Google Scholar